Free Trial
CVE:HEM

Hemostemix (HEM) Stock Price, News & Analysis

Hemostemix logo
C$0.10 +0.01 (+5.56%)
As of 05/1/2025 03:00 PM Eastern

About Hemostemix Stock (CVE:HEM)

Key Stats

Today's Range
C$0.09
C$0.10
50-Day Range
C$0.09
C$0.18
52-Week Range
C$0.04
C$0.43
Volume
249,000 shs
Average Volume
523,613 shs
Market Capitalization
C$13.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Receive HEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hemostemix and its competitors with MarketBeat's FREE daily newsletter.

HEM Stock News Headlines

Hemostemix Inc. (HEM.V)
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
Hemostemix Licenses CytoImmune's BioReactor Technologies
Hemostemix Inc. (HMTXF)
See More Headlines

HEM Stock Analysis - Frequently Asked Questions

Hemostemix's stock was trading at C$0.12 at the start of the year. Since then, HEM shares have decreased by 20.8% and is now trading at C$0.10.
View the best growth stocks for 2025 here
.

Shares of HEM stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hemostemix investors own include Iplayco (IPC), Capricor Therapeutics (CAPR), Golden Share Resources (GSH), PharmaCyte Biotech (PMCB), Algernon Pharmaceuticals (AGNPF), Defense Metals (DFMTF) and NIO (NIO).

Industry, Sector and Symbol

Stock Exchange
CVE
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
CVE:HEM
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
C$-4,997,779.56
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$0.01 per share
Price / Cash Flow
10.77
Book Value
C($0.10) per share
Price / Book
-0.95

Miscellaneous

Free Float
N/A
Market Cap
C$13.84 million
Optionable
Not Optionable
Beta
0.20
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (CVE:HEM) was last updated on 5/2/2025 by MarketBeat.com Staff
From Our Partners